Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Delivers Nicotine to Brain Faster

September 5, 2018 13:06:43
  • Ability to cross blood brain barrier – now confirmed – is significant for possible treatment of central nervous system diseases
  • LXRP may also be able to deliver micro nicotine doses, as per developing FDA policies
  • LXRP completes formation of wholly owned subsidiary, Lexaria Nicotine Corp., to better commercialize opportunities
  • The company is a technology disrupter and has applied for new U.S. patent on its delivery process; it plans to out-license and develop future products

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has been confirmed in analysis of a second generation lab study on 40 rats to transport 195 percent more nicotine, reaching peak levels at a four times faster rate to brain tissue than controls (http://nnw.fm/6vu3X). Originally, the tests were focused on developing products for nicotine delivery or smoking alternatives (http://nnw.fm/z3Dy1). Now, it appears that the technology could also potentially apply to treatment of nervous system diseases, such as Alzheimer’s.

The blood brain barrier is formed by microvascular endothelial cells, which form a layer or lining inside blood vessels and exist to block circulating toxins or…

Read More>>

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office